# Risk: __Delayed drug development__ (PBN__Risk_1801)

## Property: has_RiskSubject

* [researchers](../Stakeholder/PBN__Stakeholder_2)
* [pharmaceutical companies](../Stakeholder/PBN__Stakeholder_124)

## Property: has_RiskISO_Impact

* [Biodiversity and ecosystem services](../RiskISO/PBN__RiskISO_Purpose_4)

## Property: has_RiskSource

* [naseem_exploring_2020](../Article/PBN__Article_131)

## Property: has_RiskName

Limited treatment options and prolonged pandemic

## Property: has_RiskHealth

* [physical](../RiskHealth/PBN__RiskHealth_0)

## Property: has_RiskGBN

* [No](../RiskGBN/PBN__RiskGBN_0)

## Property: has_RiskTechnology

* [none](../Technology/PBN__Technology_35)

## Property: has_RiskOwner

* [researchers](../Stakeholder/PBN__Stakeholder_2)
* [drug developers](../Stakeholder/PBN__Stakeholder_1200)

## Property: has_RiskType

* [technological](../RiskType/PBN__RiskType_5)

## Property: has_RiskDescription

Slow process of drug testing and discovery

## Property: has_RiskISO_Purpose

* [Economy and sustainable production and consumption](../RiskISO/PBN__RiskISO_Impact_10)

## Property: has_RiskMitigation

* [Utilize AI methods for faster drug testing and discovery](../RiskMitigation/PBN__RiskMitigation_2379)

